期刊
THERANOSTICS
卷 5, 期 6, 页码 631-642出版社
IVYSPRING INT PUBL
DOI: 10.7150/thno.11389
关键词
Stem Cell Therapy; Theranostic; Pro-survival; Mesoporous Silica Nanoparticles
资金
- NHLBI [HL117048]
- Burroughs Wellcome Fund [1011172]
- NIH [S10-OD010344, U54-CA151459, P50-CA114747]
- Victorian government of Australia
- Engineering and Physical Sciences Research Council [EP/M004414/1, 1386302, EP/I020861/1] Funding Source: researchfish
- EPSRC [EP/M004414/1, EP/I020861/1] Funding Source: UKRI
- NATIONAL CANCER INSTITUTE [U54CA151459, P50CA114747] Funding Source: NIH RePORTER
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R00HL117048, K99HL117048] Funding Source: NIH RePORTER
- OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [S10OD010344] Funding Source: NIH RePORTER
Increasing cell survival in stem cell therapy is an important challenge for the field of regenerative medicine. Here, we report theranostic mesoporous silica nanoparticles that can increase cell survival through both diagnostic and therapeutic approaches. First, the nanoparticle offers ultrasound and MRI signal to guide implantation into the peri-infarct zone and away from the most necrotic tissue. Second, the nanoparticle serves as a slow release reservoir of insulin-like growth factor (IGF)-a protein shown to increase cell survival. Mesenchymal stem cells labeled with these nanoparticles had detection limits near 9000 cells with no cytotoxicity at the 250 mu g/mL concentration required for labeling. We also studied the degradation of the nanoparticles and showed that they clear from cells in approximately 3 weeks. The presence of IGF increased cell survival up to 40% (p<0.05) versus unlabeled cells under in vitro serum-free culture conditions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据